Response to Intravenous Allogeneic Equine Cord Blood-Derived Mesenchymal Stromal Cells Administered from Chilled or Frozen State in Serum and Protein-Free Media.
Authors: Williams Lynn B, Co Carmon, Koenig Judith B, Tse Crystal, Lindsay Emily, Koch Thomas G
Journal: Frontiers in veterinary science
Summary
# Editorial Summary Mesenchymal stromal cells derived from equine umbilical cord blood are increasingly used in regenerative medicine, yet their safety profile during transport and administration remains incompletely characterised. This study evaluated two carrier solutions—HypoThermosol FRS and CryoStor CS10—designed to preserve cell viability during chilled or frozen transport, testing both the solutions alone and when carrying 50 million allogeneic cord blood-derived MSCs in nine ponies across three sequential protocols. Over seven days of monitoring including physical examination, full blood counts, serum biochemistry, coagulation panels, and lymphocyte subset analysis, neither carrier solution nor the MSCs triggered clinical abnormalities, haematological changes, or biochemical derangements; both solutions maintained equivalent cell viability regardless of storage method. However, allogeneic MSC administration did elicit measurable immunological responses, with increased CD4+ and CD8+ lymphocyte populations evident at 168 hours post-injection and decreased double-positive populations at earlier timepoints, suggesting cellular immune recognition of the foreign cells. For practitioners administering allogeneic cord blood-derived MSCs, these findings provide reassurance regarding short-term safety using either carrier medium, though the documented lymphocyte response warrants consideration when treating immunocompromised individuals or interpreting post-treatment inflammatory markers. The immunological activation observed—whilst clinically silent in this cohort—indicates that recipient immune priming may occur with repeated allogeneic treatments, making autologous cell sourcing or immunologically matched products potentially advantageous for long-term regenerative protocols.
Read the full abstract on PubMed
Practical Takeaways
- •Both HTS-FRS and CS10 are safe carrier media for transporting and administering cord blood-derived MSCs to horses; choice between them should be based on facility preference and logistics
- •Allogeneic MSC treatments do not cause observable clinical problems, but lymphocyte activation occurs—monitor long-term outcomes and consider autologous or HLA-matched cells for repeated treatments
- •Current data supports safe IV administration of chilled or frozen cord blood MSCs in clinical practice at doses used in this study
Key Findings
- •HypoThermosol FRS and CryoStor CS10 carrier solutions did not elicit clinical, hematological, or biochemical abnormalities when administered intravenously to ponies
- •Both carrier solutions maintained cord blood-derived MSC viability equally well following hypothermic or frozen transport conditions
- •Allogeneic CB-MSC administration resulted in increased CD4+ and CD8+ lymphocyte populations at 168 hours post-injection, suggesting minor immune stimulation despite absence of clinical signs
- •No short-term adverse reactions were observed with either carrier solution at the tested dose of 5×10⁷ cells